Assoc Prof Chan Cheah is passionate and driven. He wants blood cancer patients in Western Australia to have the same opportunity to access new treatments as patients in other parts of Australia. He knows too
The treatment of blood cancer has come a long way in a short period of time. It was not so long ago that precision medicine and immunotherapy were just a concept, now they are very
The scientific journal Blood recently published a commentary by Dr Michael Bishop examining the effects of chimeric antigen receptor T-cell (CAR T-cell) therapy in follicular lymphoma patients. Below is a summary of the main findings.
Dr Stephen Nutt is a recipient of the Leukemia & Lymphoma Society – Snowdome Foundation – Leukaemia Foundation Translational Research Project Grant. He is an immunologist that has looked at cell survival and turned it
Dr Charles Mullighan is an Australian who found his way to the USA to pursue his passion for research into leukaemia. Charles is leading the way in finding a cure to paediatric leukaemia so we
Dr Ashwin Unnikrishnan is one of the recipients of the “Leukemia & Lymphoma Society-Snowdome Foundation-Leukaemia Foundation (LLS-SF-LF) Translational Research Project” Grants. His project is in the area of myelodysplastic syndrome (MDS). He kindly took time
The Snowdome Foundation has joined forces with the Leukaemia Foundation and America’s The Leukemia & Lymphoma Society (LLS) to fund blood cancer research projects with Australian researchers through the LLS Translational Research Program (TRP). The TRP is an
Knowing Pathology recently interviewed both Nicole Brookes and Dr Piers Blombery to get an understanding of how pathology is helping blood cancer patients. The article below is a wonderful insight into how research and the
“You have the opportunity to help one patient in front of you when you are a clinician, but when working in the laboratory you have the opportunity to help millions of patients when you make
In December 2018 the Australian Therapeutic Goods Administrator (TGA) approved the use of chimeric antigen receptor T cell (CAR-T cell) therapy for two types of blood cancer, diffuse large B cell lymphoma (DLBCL) and B
